2026年9月30日 10:15 ET 发布 · 更新于 1 个月前 · 3 个来源
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC Markets
·
原始报道
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
原文